Genetic Testing for Breast Cancer: Who Actually Needs It?

What Genetic Testing Is Actually Looking For

Most people have heard of BRCA1 and BRCA2 — the two genes that get all the attention. But here's what often gets lost: everyone has these genes. They're tumor-suppressor genes, meaning their normal job is to help repair damaged DNA and keep cells from growing out of control. The problem arises when a pathogenic variant — what used to be called a mutation — is inherited. That variant essentially puts one of your cellular repair mechanisms on the fritz from birth.

A woman with a BRCA1 pathogenic variant has roughly a 50–72% lifetime risk of developing breast cancer, compared to about 13% in the general population. Those numbers are real, and they matter. But BRCA1 and BRCA2 aren't the whole story anymore. Expanded panel tests now look at dozens of other genes — PALB2, ATM, CHEK2, CDH1, and more — each carrying its own level of risk. Some are high-risk, some moderate. Your genetic counselor will walk you through exactly what any positive finding means for your specific situation.

• BRCA1 and BRCA2 are the most studied high-risk genes
• Expanded panels can test 20–80+ genes at once
• Having a variant doesn't guarantee cancer — it raises probability
• Not all variants are equal; some are 'variants of uncertain significance'

The Red Flags in Your Family History That Warrant a Conversation

Family history is the starting point, but it's more nuanced than 'someone in my family had breast cancer.' Breast cancer is common — roughly 1 in 8 American women will develop it over a lifetime — so one distant relative diagnosed at 68 doesn't automatically signal a hereditary syndrome. What raises the concern level is a pattern.

Think about first- and second-degree relatives: parents, siblings, children, grandparents, aunts, uncles. Ask yourself: Was anyone diagnosed before 50? Did anyone have breast cancer in both breasts? Is there ovarian cancer anywhere in the picture? What about male breast cancer — because yes, men can carry and be affected by BRCA variants too? Ashkenazi Jewish ancestry is also a recognized risk factor, since certain founder mutations are more common in that population. If two or three of these flags apply to your family, that's worth bringing up at your next appointment.

One thing people often overlook: your father's side counts just as much as your mother's. A BRCA variant can be inherited from either parent. Some people dismiss a strong paternal family history because they think breast cancer is only a 'maternal line' issue. It isn't.

• Breast cancer diagnosed under age 50
• Triple-negative breast cancer at any age
• Ovarian, fallopian tube, or primary peritoneal cancer in the family
• Male breast cancer in any relative
• Multiple relatives with breast cancer across generations
• Ashkenazi Jewish ancestry combined with any cancer history

Current US Guidelines: Who Gets Referred for Testing?

The US Preventive Services Task Force (USPSTF) recommends that primary care providers screen women with a personal or family history suggesting increased risk and refer those who screen positive to genetic counseling. The USPSTF does not recommend routine testing for women whose family history doesn't suggest hereditary risk. In plain terms: the testing isn't for everyone, and that's actually fine.

The National Comprehensive Cancer Network (NCCN) guidelines go into more granular detail for oncology settings. They lay out specific criteria — things like a first-degree relative with a known BRCA variant, a personal history of breast cancer before 46, or having had ovarian cancer at any age. If you've already been diagnosed with breast cancer, your treatment team will almost certainly discuss genetic testing as part of your care plan, because the results can directly influence treatment decisions.

Here's the practical takeaway: you don't need to self-diagnose your risk level before making an appointment. Just compile what you know about your family history — cancer types, ages at diagnosis, which relatives — and bring it to your doctor or request a referral to a genetic counselor. They have validated risk-assessment tools, like the Tyrer-Cuzick model, that do the heavy lifting.

How Testing Actually Works — It's Not Complicated

The test itself is a saliva sample or a simple blood draw. That's it. You spit into a tube or get a small vial of blood taken, and a lab analyzes your DNA. Results typically come back in two to four weeks. What takes more time — and what you really shouldn't skip — is the genetic counseling that happens before and after.

A genetic counselor is a master's-level specialist trained specifically in hereditary conditions. Before the test, they help you understand what results could mean, think through how you'd feel about different outcomes, and consider whether other family members should be involved. After the test, they help you interpret results that are rarely black-and-white. A 'variant of uncertain significance,' for example, sounds alarming but means the lab found a change they simply don't have enough data on yet — it's not a positive result.

Cost can be a barrier. Many major insurers cover testing when there's a clinical indication. If you're uninsured or underinsured, programs like Color Genomics and some academic medical centers offer subsidized or low-cost options. Don't let cost be the thing that stops the conversation before it starts.

A Positive Result: What Happens Next?

A positive result isn't a diagnosis. It's information — and information you can act on. Options range across a spectrum. Increased surveillance is usually the first step: more frequent mammograms, breast MRI starting at 25 or 30, and closer monitoring from your medical team. For some people, that's enough to feel confident.

Risk-reducing surgeries — prophylactic mastectomy and, for BRCA1/2 carriers, prophylactic salpingo-oophorectomy — are options that some women choose. These decisions are deeply personal and involve long conversations with surgical and oncology teams. There's no right answer that applies to everyone.

Chemoprevention is another tool. Tamoxifen, a medication we carry at Chep Meds USA, has been FDA-approved for breast cancer risk reduction in high-risk premenopausal women for decades. It works by blocking estrogen receptors in breast tissue, which can significantly lower the chance of developing hormone receptor-positive breast cancer. For BRCA2 carriers in particular, whose tumors tend to be hormone receptor-positive, tamoxifen is often part of the conversation. It's not a casual medication — your doctor will weigh your individual risk profile, medical history, and other factors — but it's a legitimate, evidence-backed option worth discussing if you test positive or fall into a high-risk category.

• Enhanced screening (MRI + mammogram annually)
• Risk-reducing medication such as tamoxifen or raloxifene
• Prophylactic surgery — a major decision requiring specialist input
• Lifestyle modifications (maintaining healthy weight, limiting alcohol)
• Cascade testing for blood relatives who may also carry the variant

What a Negative Result Does and Doesn't Mean

People sometimes walk away from a negative test thinking they're completely off the hook. That's not quite right. A true negative — where a known family variant was searched for and not found in you — is very reassuring. But if your family history is strong and no variant has ever been identified in your family, a negative result just means the lab didn't find a variant in the genes they tested. The underlying risk from your family history doesn't disappear.

You'll still want to follow screening recommendations appropriate for your age and personal risk. For most women, that means annual mammograms starting at 40, per the American Cancer Society. Your doctor may recommend starting earlier based on other factors. Don't treat a negative result as permission to stop paying attention.

The Privacy Question People Don't Ask Enough

One thing that holds people back from testing is fear about what happens to the results. Will this affect my insurance? Can my employer find out? These are fair concerns, and the answer is more protective than many people realize. The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers from discriminating based on genetic information. GINA does not, however, cover life insurance, disability insurance, or long-term care insurance — so if those policies matter to you, it's worth discussing timing with your genetic counselor.

Your results are part of your medical record and subject to HIPAA protections. Who you choose to share results with — including family members who might benefit from knowing — is entirely your decision. A genetic counselor can help you think through those family conversations, which can be genuinely complicated.

Common questions